Posts tagged HIV therapy
HIV Infected Stimulant Users
9 years ago
by ADMIN
in HIV Research
HIV Infected Stimulant Users: Treatment Benefits
Some studies in the mid 90’s pointed to evidence that stimulants – such as cocaine or methamphetamine – were causing the antiretroviral therapy to be less effective against HIV. For example, HIV infected stimulant users were developing AIDS more frequently than non-using infected. The most recent studies, however, have shown that this evidence was misleading, and that antiretroviral medication does indeed have the same effects on stimulant users and non-users. The evidence was not taking into account the difficulty many stimulant users, especially those who abused these kinds of drugs, have had to obtain their needed medication. Much of this stemmed from a belief that users of these kinds of drugs would also abuse the antiretroviral medication, or would not take the medication properly.
The new data, collected between 1996 and 2012, shows that stimulant users frequently take their medication at the proper intervals, even when they are unable to lessen or stop their respective stimulant substance. This proved that not only do these infected take their medication as directed, the effects of the medication are nearly identical to non-using infected patients. The concern that still lingers concerning HIV infected stimulant users, however, is the spread of the disease due to their drug-related activities. The latest study, out of the Multicenter AIDS Cohort Study (an ongoing study of HIV infected men who have sex with men), has concluded that the biggest focus researchers should now have when dealing with HIV infected stimulant users is education and prevention. One thing the study noticed is that stimulant users are more likely to be open and forthright with their physician—if that doctor is a specialist in HIV and infectious diseases (as opposed to a general physician or one who specializes in drug use and abuse). Even when the patients are not ready to go to a group or doctor for help with their drug habits, they are ready to work with an HIV specialist to ensure their life with HIV is as healthy as possible.
New Anti-HIV Drugs
9 years ago
by ADMIN
in HIV Therapy
New Anti-HIV Drugs: Research in Stopping AIDS
In December of 2013, researchers at the University of Minnesota published some very striking and uniformly positive findings in the fight against HIV. They discovered several compounds that uniquely targeted HIV cells. These compounds – ribonucleoside analogs 8-azaadenosine, formycin A, 3-deazauridine, 5-fluorocytidine and 2’-C-methylcytidine – stop HIV replication by blocking DNA synthesis. This is achieved by causing the HIV cells to drop their DNA load before they are ready to and not within blood cells. The compounds also cause the HIV cells to mutate so rapidly that the cells essentially mutate themselves into extinction. The findings were a surprise to most of the anti-HIV research community, because the compounds in question were not on anyone’s radar. In fact, they seemed to have no potential for stopping HIV. Another major benefit to these compounds is the low cost of synthesizing them into new anti-HIV drugs. This is always an important factor, as it lessens the burden for the future prevention and treatment of HIV.
In fact, this is what has been occurring over the past year. The new anti-HIV drugs, which were synthesized version of these compounds, have been introduced in tangent with currently approved HIV medications. So far, the reports have been positive. Although the drugs do not fully eradicate HIV from an infected person’s system, the new drugs can be used along with lower doses of more expensive medications. With this tandem approach, the infection is kept low and extremely manageable. Having a minimal viral load results in low immune activity and prevents the virus cells from spreading throughout the body. Because of this symptoms are virtually absent. This translates into lower costs for a lifelong regimen of anti-HIV medication, both for the individual patients and for health care systems worldwide.
HIV Requires Early Treatment
9 years ago
by ADMIN
in HIV Research
HIV Requires Early Treatment: B Cells Are the Key in Infected Subjects
It was very clear early on in HIV research that the earlier treatment for the disease begins, the better a person will respond to the antiretroviral medications. However, the exact reason for this has eluded researchers. A recent study of the blood of nearly 100 treated and untreated HIV-infected volunteers has provided a possible explanation as to why HIV requires early treatment. The study underscored the need to begin treatment as close to viral exposure as possible, as it not only means saved lives but it also can ensure a healthier and better quality of life for those living with HIV.
B cells are immune system cells that produce antibodies to viruses like HIV. However, in the above mentioned study, some previously unknown characteristics of B cells were discovered. The researchers found that the antibodies the B cells produced in infected but untreated people were abnormal. These B cells were more activated, more unstable and unresponsive to further stimulation as compared to normal B cells. This may explain why HIV antibodies naturally produced in the body are unable to clear the infection.
The research further discovered that those who were HIV infected—but had undergone early antiretroviral treatment—had B cell responses that were dramatically different from those who had not received treatment. In the treated patients their antibodies were normal, although there were less of them than in the untreated volunteers. The treated patient’s antibodies were also stronger and more effective on the HIV cells. This resulted in a lower amount of virus in the blood, known as a viral load. It also meant a low level of immune activation, which results in a stronger and healthier immune system. All of this underscores the fact that HIV requires early treatment. Antiretroviral medication, when prescribed during the early stages of the infection can stabilize the mutation of any cells – T cells or B cells. This means that the infected person’s natural immune defenses will be robust and better able to defend against HIV for the long run.
Interferon in HIV Treatment
9 years ago
by ADMIN
in HIV Therapy
Interferon in HIV Treatment: It Still Has Its Place
Interferons (IFN) are cells that are naturally produced in the body to fight against viral infections. When working as intended, interferons ultimately ward off and destroy the virus in the body. In fact, they are the main natural defense against cold and flu viruses. One major downside to interferon, though, is the harmful effects they have on the body while fighting viruses. You know that achy, nauseous feeling you get when you have the flu? Many of the symptoms equated with the flu actually don’t come from the virus itself; it comes from the effects of your body’s production of interferon cells. Interferon creates an inflammation in the body as it works, causing the ache that you experience. This negative side effect is a major reason why researchers have abandoned general use of interferon in HIV treatment.
Though this medication was used for several years as the only treatment of hepatitis C, new medications that have fewer side effects, a higher rate of success, and a shorter regimen period have replaced interferon treatment. However, in an attempt to keep the benefits of interferon treatment, researchers are trying to eliminate the negative side effects of IFNs while still keeping its effective virus-attacking properties intact. The results were mixed.
Researchers were successful in eliminating a majority of the side effects of IFN therapies, but they learned that when the inflammation is removed it affects interferon’s efficacy against viruses. It was also learned that interferon in HIV treatment, if given shortly after exposure to HIV, can be very effective—this despite the fact that general IFN treatment is still not the most effective way to manage HIV. Thus, it is important to keep in mind the type of treatment that an HIV patient is administered, and the timing of the treatment.
Mutating HIV Into Extinction
Mutating HIV into Extinction: One Answer to the Dilemma of HIV
In the late 1990’s a group of scientists and researchers faced with the dilemma of HIV and its resistance to a cure, decided to try to force the virus to over-mutate. The idea was to cause HIV to mutate at a rate much greater than the average HIV cell normally does, thus making the cells weaker and more prone to being eradicated. Essentially, they were attempting to cure people by mutating HIV into extinction. Many thought this approach would ultimately prove fruitless, but they pressed on.
Fast forward to 2011 and we find that, indeed, the group has developed a drug that causes rapid mutation in HIV cells. In the lab the drug forced a mutation explosion such that the HIV cells could no longer produce enough protein to survive. This essentially ‘killed’ the virus (although, technically, viruses are not alive in the first place, which is one of the reasons they are so difficult to eliminate). In clinical trials, however, the mutation was not great enough to cause the test patients’ HIV cells to collapse.
In a new study, released in July in Proceedings of the National Academy of Sciences (PNAS), the researchers discovered how the drug – currently known as KP1212 – was able to cause the HIV cells to mutate beyond their normal rate. Armed with this new knowledge, they are confident that they will be able to strengthen the effects of the drug and eliminate the HIV cells on a permanent basis. If they are successful we are talking about an actual cure for HIV.
HIV cells normally mutate quite frequently due to the way HIV reproduces. HIV makes copies of its genetic material, which is very error-prone and unstable, in a rapid mutation that actually helps the virus cells evade elimination from both the body’s immune system and man-made drugs. If HIV can essentially be forced into overdrive (roughly double the normal mutation rate), it will cause weaknesses that will result in the immediate elimination of HIV. Or, at the very least, cause the virus to become highly susceptible to drug elimination. This kind of forced over-mutation can, and in some cases already does, work for other viruses. For example, this is how Ribavirin works in patients with the hepatitis C virus. Similarly, some of the drugs developed for certain strands of influenza work in the same way. All of this good news suggests that we could be on the road to mutating HIV into extinction.
